Levels of amphotericin B lipid formulations in ascites

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 1163-1164

  Weiler, Stefan ^a   Bellmann Weiler, Rosa ^a   Dunzendorfer, Stefan ^a   Joannidis, Michael ^a   Bellmann, Romuald ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Ascitic fluid; Clinical pharmacokinetics; Peritoneal fluid; Polyene antifungals; Target site penetration, lipid formulations

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX;

ADULT; AGED; ASCITES FLUID LEVEL; CASE REPORT; CRITICALLY ILL PATIENT; DRUG FORMULATION; DRUG PERITONEAL FLUID LEVEL; HUMAN; KIDNEY FAILURE; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LYMPHOMA; MALE; MYCOSIS; PNEUMONIA; SEPTIC SHOCK;

ADULT; AGED; AMPHOTERICIN B; ASCITIC FLUID; CRITICAL ILLNESS; HUMANS; MALE; MIDDLE AGED;

EID: 54549087945     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn306     Document Type: Letter

References (6)

1. van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother 2007; 59: 952-6.
2. Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis 2003; 36: 1500-1.
3. Vogelsinger H, Weiler S, Djanani A et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother 2006; 57: 1153-60.
4. Egger P, Bellmann R, Wiedermann CJ. Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 760: 307-13.
5. Rex JH, Pfaller MA, Barry AL et al. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother 1995; 39: 40-4.
6. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.